Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)

NCT03118570 is registered in ClinicalTrials.gov with Ultragenyx Pharmaceutical Inc as lead sponsor.

NCT NCT03118570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03118570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
Lead sponsor
Ultragenyx Pharmaceutical Inc
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2017
Completion date
November 12, 2020
Enrollment
112 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta type iii, osteogenesis imperfecta type iv, osteogenesis imperfecta, type i